摘要
目的 探讨瑞舒伐他汀治疗血管性痴呆（VD）的效果及对血管内皮功能的影响。方法 选取2014年12月～2016年3月湖北省黄石市中心医院140例符合纳入标准的VD患者作为研究对象,按照随机数字表法分为两组,每组70例。对照组患者给予常规治疗,观察组在对照组基础上给予瑞舒伐他汀辅助治疗,疗程均为3个月。采用简易精神状态评价量表（MMSE）评价患者认知功能。比较两组临床疗效、MMSE积分、血清内皮素-1（ET-1）、一氧化氮（NO）水平。结果 观察组患者总有效率高于对照组（87.1%和71.4%,P〈0.05）。治疗后,观察组患者MMSE积分较对照组升高[（20.7±2.4）和（18.9±2.8）分],血清ET-1水平较对照组降低[（75.1±14.0）和（94.5±16.4）ng/L],NO水平较对照组升高[（53.5±8.7）和（43.8±8.2）μmol/L],差异有统计学意义（P〈0.05）。结论 瑞舒伐他汀治疗VD患者能提高有效率,能显著改善患者认知功能及血管内皮功能。
Objective To investigate effects of Rosuvastatin in the treatment of vascular dementia （VD） and influence on vascular endothelial function. Methods 140 patients with VD from Central Hospital of Huangshi City in Hubei Province met the inclusion criteria from December 2014 to March 2016 were selected as research objects, they were divided into two groups by using random number table method. Each group was 70 cases. The conventional treatment was used in control group, on the basis of control group, Rosuvastatin treatment was applied in observation group. The course of treatment was 3 months. Mini-mental state examination （MMSE） was employed to assess cognitive function. The curative efficacy, MMSE score, ET-1 and NO were compared between two groups. Results Total efficacy rate in observation group was higher than that in control group （87.1% and 71.4%, P 〈 0.05）. After treatment, MMSE score [（20.7±2.4） vs （18.9±2.8） points] in observation group was higher than that in control group, ET-1 [（75.1±14.0） vs （94.5±16.4） ng/L] in observation group was lower than that in control group, NO [（53.5＋8,7） vs （43.8±8.2） Ixmol/L] in observation group was higher than that in control group, with statistical differences （P 〈 0.05）. Conclusion Rosuvastatin in the treatment of vascular dementia patients can improve the efficiency, can significantly improve cognitive function and vascular endothelial function.
出处
《中国医药导报》
CAS
2016年第33期137-140,共4页
China Medical Herald
基金
湖北省黄石市医药卫生科技研究项目(2013-47)
